Table 2. Clinicopathological variables of patients undergoing liver transplantation for hilar cholangiocarcinoma.

Thirty four patients who underwent an attempt to surgically remove the tumor prior to transplantation and 8 patients with missing variables were excluded.

Variable	Patients transplanted for hilar cholangiocarcinoma n = 105		P-value
	Group A n = 28 Patients complying with the Mayo Clinic selection criteria for LT, without neo-adjuvant therapy	Group B n = 77 Patients not complying with the Mayo Clinic selection criteria.
Mean age in years (± SD)	46 (± 9)	51 (± 10)	0.62
Gender:
Male	18 (64%)	55 (71%)	0.48
Female	10 (36%)	22(39%)
Neo-adjuvant therapy
Yes	0 (0%)	16 (21%)	0.008
No	28 (100%)	59 (79%)
Percutaneous or surgical biopsy prior to LT
Yes	0 (0%)	35 (49%)	0.001
No	28 (100%)	36 (51%)
Adjuvant therapy
Yes	0 (0%)	12 (17%)	0.02
No	28 (100%)	60 (83%)
pT classification
pT1	1 (4%)	6 (8%)	0.51
pT2	13 (48%)	30 (40%)
pT3	13 (48%)	35 (47%)
pT4	0 (0%)	4 (5%)
pN classification
pN0	28 (100%)	34 (46%)	0.001
pN1	0 (0%)	37 (50%)
pN2	0 (0%)	3 (4%)
Distal bile duct margin tumor free
Yes	26 (93%)	66 (89%)	0.58
No	2 (7%)	8 (11%)
PSC
Yes	6 (24%)	NA	-
No	19 (76%)	NA
Median time on waiting list in days*	30 (range: 1–870)	NA	-
Median preoperative CA19.9 value in kU/L**	48 (range: 4–1410)	NA	-
90 Day mortality
Yes	3 (11%)	13 (17%)	0.44
No	25 (89%)	64 (83%)

Abbreviations: LT: liver transplantation, PSC: primary sclerosing cholangitis, NA: not available

*Data available for 25 patients.

**Data available for 16 patients.